Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous Immunoglobulin for CIDP
NCT02465359Completed
- Sponsor
- University of South Florida
- Start
- Sep 2014
- Primary completion
- Mar 2018
- Modality
- Biologic
- Countries
- 1
01
Overview
Open-label, single-arm trial of polyvalent human immunoglobulin in chronic inflammatory demyelinating polyneuropathy (CIDP), sponsored by University of South Florida. Primary endpoint: Relapse of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Symptoms at 24 weeks. Started Sep 2014; status: completed.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on NCT02465359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02465359.